David Bennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David Bennett has a total of 265 co-authors. Here are the top co-authors by number of shared publications:
Paola Rottoli
Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena, Siena, Italy
26 shared publicationsAntonella Fossi
Respiratory Diseases Unit, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy
25 shared publicationsElena Bargagli
Respiratory Diseases Unit, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy
25 shared publicationsRosa Metella Refini
Respiratory Diseases Unit, University Hospital of Siena (AOUS), Siena, Italy
21 shared publications- Elena Bargagli
University of Siena
20 shared publications Luca Luzzi
Thoracic Surgery and Lung Transplantation Unit, University Hospital of Siena, Siena, Italy
15 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
When BAL meets CT scan: enhancing noninvasive diagnosis of acute cellular rejection after lung transplantation
Acute cellular rejection (ACR) is a common complication after lung transplantation (LTX) and it is considered a risk factor for chronic lung allograft dysfunction (CLAD). Lung transbronchial biopsy is still the gold standard for a correct diagnosis of ACR. The aim of the present study was to evaluate the predictive role of bronchoalveolar lavage (BAL) cellular composition in combination with CT scan features for the diagnosis of ACR. We retrospectively evaluated all LTX recipients who underwent transbronchial biopsies combined with BAL procedures and CT scan at a single Institution between January 2019 and October 2024 (n = 169). ACR histological diagnosis was made according to current guidelines, BAL analysis included percentage of cellular composition, lymphocytes' typing and microbiology. A qualitative analysis of specific CT was conducted by an expert thoracic radiologist. Among the 169 biopsies analyzed, 34% showed acute cellular rejection (ACR), predominantly grade A1 (68%). Patients with ACR exhibited significantly higher lymphocyte percentages in BAL (p = 0.025), and the cutoff of 25% showed 22% sensibility and 92% specificity for the diagnosis of ACR. Combing BAL findings with CT features, patients with lymphocyte ≥ 25% in BAL and concomitant pleural effusion showed 95.7% specificity of ACR. Infections were associated with elevated neutrophil levels in BAL (p = 0.026); eosinophil levels were significantly higher in patients with significant ACR (grade ≥ 2) and concomitant infection than those with infection only (p = 0.0014). BAL cellular composition proved to be a strong predictive tool for the diagnosis of ACR. The lymphocyte threshold of 25% was able to distinguish patients with ACR, while the combination of increased BAL lymphocytes with ACR associated CT scan abnormalities especially pleural effusion significantly enhanced diagnostic accuracy. Elevated eosinophil levels were associated to more severe rejection and concomitant infection, highlighting their crucial role in the alloreactive immune response. These findings suggest the role of BAL and CT scan in combination as a valuable diagnostic tool in ACR diagnosis, although histological confirmation remains the gold standard.
- 19 March 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessWhen BAL meets CT scan: enhancing noninvasive diagnosis of acute cellular rejection after lung transplantation
Acute cellular rejection (ACR) is a common complication after lung transplantation (LTX) and it is considered a risk factor for chronic lung allograft dysfunction (CLAD). Lung transbronchial biopsy is still the gold standard for a correct diagnosis of ACR. The aim of the present study was to evaluate the predictive role of bronchoalveolar lavage (BAL) cellular composition in combination with CT scan features for the diagnosis of ACR. We retrospectively evaluated all LTX recipients who underwent transbronchial biopsies combined with BAL procedures and CT scan at a single Institution between January 2019 and October 2024 (n = 169). ACR histological diagnosis was made according to current guidelines, BAL analysis included percentage of cellular composition, lymphocytes' typing and microbiology. A qualitative analysis of specific CT was conducted by an expert thoracic radiologist. Among the 169 biopsies analyzed, 34% showed acute cellular rejection (ACR), predominantly grade A1 (68%). Patients with ACR exhibited significantly higher lymphocyte percentages in BAL (p = 0.025), and the cutoff of 25% showed 22% sensibility and 92% specificity for the diagnosis of ACR. Combing BAL findings with CT features, patients with lymphocyte ≥ 25% in BAL and concomitant pleural effusion showed 95.7% specificity of ACR. Infections were associated with elevated neutrophil levels in BAL (p = 0.026); eosinophil levels were significantly higher in patients with significant ACR (grade ≥ 2) and concomitant infection than those with infection only (p = 0.0014). BAL cellular composition proved to be a strong predictive tool for the diagnosis of ACR. The lymphocyte threshold of 25% was able to distinguish patients with ACR, while the combination of increased BAL lymphocytes with ACR associated CT scan abnormalities especially pleural effusion significantly enhanced diagnostic accuracy. Elevated eosinophil levels were associated to more severe rejection and concomitant infection, highlighting their crucial role in the alloreactive immune response. These findings suggest the role of BAL and CT scan in combination as a valuable diagnostic tool in ACR diagnosis, although histological confirmation remains the gold standard.
- Open Access
- 17 September 2025
- Published by MDPI AG in Transplantology
- Vol. 6 (3) , 28
Assessing Short- and Medium-Term Outcomes of Lung Transplantation in Elderly Recipients: A Comparative Age-Based Analysis
Background/Objectives: This study aims to analyze the short- and medium-term outcomes of lung transplantation (LT) in recipients aged 65 years and older, comparing them with those of younger individuals. The primary endpoints were 90-day and 1-year survival, while secondary measures included perioperative complications and chronic lung allograft dysfunction (CLAD) rates. Methods: A retrospective cohort analysis was conducted on 135 patients who underwent LT at the Siena Lung Transplant Center between January 2013 and December 2023. The participants were stratified into three age groups: under 60 years (Group Y), 60–65 years (Group M), and over 65 years (Group O). Outcomes assessed included ischemia times, transplant type (single or bilateral), ICU and hospital stay, postoperative complications, and CLAD incidence. The data were analyzed using non-parametric statistics, Kaplan–Meier survival curves, and correlation tests between clinical variables and survival outcomes. Results: Among the patients, 88 belonged to Group Y, 36 to Group M, and 11 to Group O. Idiopathic pulmonary fibrosis (IPF) was prevalent in older recipients (82%). Patients over 65 showed a lower prevalence of diabetes (p = 0.025) and pulmonary hypertension (p < 0.01). Bilateral LT was most common in Group Y (91%) and least in Group O (36%, p < 0.0001). Group Y had the longest maximum ischemia time (425 ± 161 min vs. 315 ± 140 min in Group O, p = 0.048). ICU stay (p = 0.289) and hospital stay (p = 0.900) did not differ significantly across groups. No group differences were observed in rates of primary graft dysfunction (p = 0.869), need for renal replacement therapy (p = 0.358), or prolonged ventilation (p = 0.609). CLAD incidence was comparable (p = 0.400), as were 90-day (p = 0.997) and 1-year survival rates (p = 0.174). Conclusions: Carefully selected patients over 65 years old can achieve similar short- and medium-term outcomes to younger LT recipients. These findings support the inclusion of older candidates in transplant programs, while highlighting the need for further research to optimize perioperative strategies and long-term management in this age group.
- 17 September 2025
- Published by MDPI AG in Transplantology
- Vol. 6 (3) , 28
Open AccessAssessing Short- and Medium-Term Outcomes of Lung Transplantation in Elderly Recipients: A Comparative Age-Based Analysis
Background/Objectives: This study aims to analyze the short- and medium-term outcomes of lung transplantation (LT) in recipients aged 65 years and older, comparing them with those of younger individuals. The primary endpoints were 90-day and 1-year survival, while secondary measures included perioperative complications and chronic lung allograft dysfunction (CLAD) rates. Methods: A retrospective cohort analysis was conducted on 135 patients who underwent LT at the Siena Lung Transplant Center between January 2013 and December 2023. The participants were stratified into three age groups: under 60 years (Group Y), 60–65 years (Group M), and over 65 years (Group O). Outcomes assessed included ischemia times, transplant type (single or bilateral), ICU and hospital stay, postoperative complications, and CLAD incidence. The data were analyzed using non-parametric statistics, Kaplan–Meier survival curves, and correlation tests between clinical variables and survival outcomes. Results: Among the patients, 88 belonged to Group Y, 36 to Group M, and 11 to Group O. Idiopathic pulmonary fibrosis (IPF) was prevalent in older recipients (82%). Patients over 65 showed a lower prevalence of diabetes (p = 0.025) and pulmonary hypertension (p < 0.01). Bilateral LT was most common in Group Y (91%) and least in Group O (36%, p < 0.0001). Group Y had the longest maximum ischemia time (425 ± 161 min vs. 315 ± 140 min in Group O, p = 0.048). ICU stay (p = 0.289) and hospital stay (p = 0.900) did not differ significantly across groups. No group differences were observed in rates of primary graft dysfunction (p = 0.869), need for renal replacement therapy (p = 0.358), or prolonged ventilation (p = 0.609). CLAD incidence was comparable (p = 0.400), as were 90-day (p = 0.997) and 1-year survival rates (p = 0.174). Conclusions: Carefully selected patients over 65 years old can achieve similar short- and medium-term outcomes to younger LT recipients. These findings support the inclusion of older candidates in transplant programs, while highlighting the need for further research to optimize perioperative strategies and long-term management in this age group.
- Open Access
- 30 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5380
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review
Lung transplantation remains the standard of care for end-stage lung disease, yet a persistent gap exists between donor lung availability and growing clinical demand. Expanding the donor pool and optimising donor lung management are therefore critical priorities. However, no universally accepted management protocols are currently in place. This narrative review examines evidence-based strategies to improve lung utilisation across three donor categories: donors after brain death (DBD), controlled donors after circulatory death (cDCD), and uncontrolled donors after circulatory death (uDCD). A systematic literature search was conducted to identify interventions targeting lung preservation and function, including protective ventilation, recruitment manoeuvres, fluid and hormonal management, and ex vivo lung perfusion (EVLP). Distinct pathophysiological mechanisms—sympathetic storm and systemic inflammation in DBD, ischaemia–reperfusion injury in cDCD, and prolonged warm ischaemia in uDCD—necessitate tailored approaches to lung preservation. In DBD donors, early application of protective ventilation, bronchoscopy, and infection surveillance is essential. cDCD donors benefit from optimised pre- and post-withdrawal management to mitigate lung injury. uDCD donor lungs, uniquely vulnerable to ischaemia, require meticulous post-mortem evaluation and preservation using EVLP. Implementing structured, evidence-based lung management strategies can significantly enhance donor lung utilisation and expand the transplantable organ pool. The integration of such practices into clinical protocols is vital to addressing the global shortage of suitable lungs for transplantation.
- 30 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5380
Open AccessStrategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review
Lung transplantation remains the standard of care for end-stage lung disease, yet a persistent gap exists between donor lung availability and growing clinical demand. Expanding the donor pool and optimising donor lung management are therefore critical priorities. However, no universally accepted management protocols are currently in place. This narrative review examines evidence-based strategies to improve lung utilisation across three donor categories: donors after brain death (DBD), controlled donors after circulatory death (cDCD), and uncontrolled donors after circulatory death (uDCD). A systematic literature search was conducted to identify interventions targeting lung preservation and function, including protective ventilation, recruitment manoeuvres, fluid and hormonal management, and ex vivo lung perfusion (EVLP). Distinct pathophysiological mechanisms—sympathetic storm and systemic inflammation in DBD, ischaemia–reperfusion injury in cDCD, and prolonged warm ischaemia in uDCD—necessitate tailored approaches to lung preservation. In DBD donors, early application of protective ventilation, bronchoscopy, and infection surveillance is essential. cDCD donors benefit from optimised pre- and post-withdrawal management to mitigate lung injury. uDCD donor lungs, uniquely vulnerable to ischaemia, require meticulous post-mortem evaluation and preservation using EVLP. Implementing structured, evidence-based lung management strategies can significantly enhance donor lung utilisation and expand the transplantable organ pool. The integration of such practices into clinical protocols is vital to addressing the global shortage of suitable lungs for transplantation.
- Open Access
- 19 June 2025
- Published by MDPI AG in Preprints.org
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review
Lung transplantation remains the standard of care for end-stage lung disease, yet a persistent gap exists between donor lung availability and growing clinical demand. Expanding the donor pool and optimising donor lung management are therefore critical priorities. However, no universally accepted management protocols are currently in place. This narrative review examines evidence-based strategies to improve lung utilisation across three donor categories: donors after brain death (DBD), controlled donors after circulatory death (cDCD), and uncontrolled donors after circulatory death (uDCD). A systematic literature search was conducted to identify interventions targeting lung preservation and function, including protective ventilation, recruitment manoeuvres, fluid and hormonal management, and ex vivo lung perfusion (EVLP). Distinct pathophysiological mechanisms—sympathetic storm and systemic inflammation in DBD, ischaemia-reperfusion injury in cDCD, and prolonged warm ischaemia in uDCD—necessitate tailored approaches to lung preservation. In DBD donors, early application of protective ventilation, bronchoscopy, and infection surveillance is essential. cDCD donors benefit from optimised pre- and post-withdrawal management to mitigate lung injury. uDCD donor lungs, uniquely vulnerable to ischaemia, require meticulous post-mortem evaluation and preservation using EVLP. Implementing structured, evidence-based lung management strategies can significantly enhance donor lung utilisation and expand the transplantable organ pool. Integration of such practices into clinical protocols is vital to addressing the global shortage of suitable lungs for transplantation.
- 19 June 2025
- Published by MDPI AG in Preprints.org
Open AccessStrategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review
Lung transplantation remains the standard of care for end-stage lung disease, yet a persistent gap exists between donor lung availability and growing clinical demand. Expanding the donor pool and optimising donor lung management are therefore critical priorities. However, no universally accepted management protocols are currently in place. This narrative review examines evidence-based strategies to improve lung utilisation across three donor categories: donors after brain death (DBD), controlled donors after circulatory death (cDCD), and uncontrolled donors after circulatory death (uDCD). A systematic literature search was conducted to identify interventions targeting lung preservation and function, including protective ventilation, recruitment manoeuvres, fluid and hormonal management, and ex vivo lung perfusion (EVLP). Distinct pathophysiological mechanisms—sympathetic storm and systemic inflammation in DBD, ischaemia-reperfusion injury in cDCD, and prolonged warm ischaemia in uDCD—necessitate tailored approaches to lung preservation. In DBD donors, early application of protective ventilation, bronchoscopy, and infection surveillance is essential. cDCD donors benefit from optimised pre- and post-withdrawal management to mitigate lung injury. uDCD donor lungs, uniquely vulnerable to ischaemia, require meticulous post-mortem evaluation and preservation using EVLP. Implementing structured, evidence-based lung management strategies can significantly enhance donor lung utilisation and expand the transplantable organ pool. Integration of such practices into clinical protocols is vital to addressing the global shortage of suitable lungs for transplantation.
- Open Access
A novel web-based tool for lung transplant patients undergoing extracorporeal photopheresis
- 1 March 2024
- Published by Edizioni Minerva Medica in Minerva Medica
- Vol. 115 (1) , 116-118
Outcome of ECMO bridge to lung transplantation: a single cohort study
Article: Outcome of ECMO bridge to lung transplantation: a single cohort study - Minerva Medica 2020 Jul 21 - Minerva Medica - Journals
- 1 March 2024
- Published by Edizioni Minerva Medica in Minerva Medica
- Vol. 115 (1) , 116-118
Outcome of ECMO bridge to lung transplantation: a single cohort study
Article: Outcome of ECMO bridge to lung transplantation: a single cohort study - Minerva Medica 2020 Jul 21 - Minerva Medica - Journals
- Open Access
Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes
The accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncological disease or unknown neoplasia found on native lungs submitted to LTX, compared to a control group. A total of 433 patients were included in the analysis, 31 with malignancies (Group 1) and 402 without neoplastic disease (Group 2). The two groups were compared in terms of short- and long-term outcomes. Patients in Group 1 were older (median age 58 years vs. 50 years, p = 0.039) and mostly affected by idiopathic pulmonary fibrosis (55% vs. 40% p = 0.002). Even though in Group 1 a lower rate of late post-operative complications was found (23% vs. 45%, p = 0.018), the median overall survival (OS) was lower compared to the control group (10 months vs. 29 months, p = 0.015). LTX represents a viable therapeutic option for patients with end-stage lung disease and a history of neoplastic disease. However, every case should be carefully debated in a multidisciplinary setting, considering oncological (histology, stage, and proper disease free-interval) and clinical factors (patient’s age and comorbidities). A scrupulous post-transplant follow-up is especially mandatory in those cases.
Open AccessLung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes
The accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncological disease or unknown neoplasia found on native lungs submitted to LTX, compared to a control group. A total of 433 patients were included in the analysis, 31 with malignancies (Group 1) and 402 without neoplastic disease (Group 2). The two groups were compared in terms of short- and long-term outcomes. Patients in Group 1 were older (median age 58 years vs. 50 years, p = 0.039) and mostly affected by idiopathic pulmonary fibrosis (55% vs. 40% p = 0.002). Even though in Group 1 a lower rate of late post-operative complications was found (23% vs. 45%, p = 0.018), the median overall survival (OS) was lower compared to the control group (10 months vs. 29 months, p = 0.015). LTX represents a viable therapeutic option for patients with end-stage lung disease and a history of neoplastic disease. However, every case should be carefully debated in a multidisciplinary setting, considering oncological (histology, stage, and proper disease free-interval) and clinical factors (patient’s age and comorbidities). A scrupulous post-transplant follow-up is especially mandatory in those cases.
- Open Access
- 12 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 1963
Anti-Cytosolic 5′-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study
Background: Anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies were proposed as a biomarker for the diagnosis of inclusion body myositis (IBM), but conflicting specificity and sensitivity evidence limits its use. Our study aimed to assess the diagnostic accuracy of anti-cN1A in a cohort of patients who underwent a myositis line immunoassay for suspected idiopathic inflammatory myopathies (IIM). We also assessed the agreement between two testing procedures: line immunoassay (LIA) and enzyme-linked immunoassay (ELISA). Materials and methods: We collected retrospective clinical and serological data for 340 patients who underwent a myositis antibody assay using LIA (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (IgG) line immunoassay) and verification with an anti-cN1A antibody assay using ELISA (IgG) (Euroimmun Lubeck, Germany). Results: The serum samples of 20 (5.88%) patients (15 females, 5 males, mean age 58.76 ± 18.31) tested positive for anti-cN1A using LIA, but only two out of twenty were diagnosed with IBM. Seventeen out of twenty tested positive for anti-cN1A using ELISA (median IQR, 2.9 (1.9–4.18)). Conclusions: Our study suggests excellent concordance between LIA and ELISA for detecting anti-cN1A antibodies. LIA may be a rapid and useful adjunct, and it could even replace ELISA for cN1A assay. However, the high prevalence of diseases other than IBM in our cohort of anti-cN1A-positive patients did not allow us to consider anti-cN1A antibodies as a specific biomarker for IBM.
- 12 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 1963
Open AccessAnti-Cytosolic 5′-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study
Background: Anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies were proposed as a biomarker for the diagnosis of inclusion body myositis (IBM), but conflicting specificity and sensitivity evidence limits its use. Our study aimed to assess the diagnostic accuracy of anti-cN1A in a cohort of patients who underwent a myositis line immunoassay for suspected idiopathic inflammatory myopathies (IIM). We also assessed the agreement between two testing procedures: line immunoassay (LIA) and enzyme-linked immunoassay (ELISA). Materials and methods: We collected retrospective clinical and serological data for 340 patients who underwent a myositis antibody assay using LIA (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (IgG) line immunoassay) and verification with an anti-cN1A antibody assay using ELISA (IgG) (Euroimmun Lubeck, Germany). Results: The serum samples of 20 (5.88%) patients (15 females, 5 males, mean age 58.76 ± 18.31) tested positive for anti-cN1A using LIA, but only two out of twenty were diagnosed with IBM. Seventeen out of twenty tested positive for anti-cN1A using ELISA (median IQR, 2.9 (1.9–4.18)). Conclusions: Our study suggests excellent concordance between LIA and ELISA for detecting anti-cN1A antibodies. LIA may be a rapid and useful adjunct, and it could even replace ELISA for cN1A assay. However, the high prevalence of diseases other than IBM in our cohort of anti-cN1A-positive patients did not allow us to consider anti-cN1A antibodies as a specific biomarker for IBM.
- 1 January 2023
- Published by Lawrence and Wishart in New Formations
- Vol. 107 (107) , 198-214
Extinction and the Anthropocene: To End Or Mend the World ? A Conversation with Claire Colebrook
- 1 January 2023
- Published by Lawrence and Wishart in New Formations
- Vol. 107 (107) , 198-214
Extinction and the Anthropocene: To End Or Mend the World ? A Conversation with Claire Colebrook